Prakt. lékáren. 2016; 12(5): 170-172 [Med. praxi. 2016;13(4):200-202]

Lipertance - a novel agent in comprehensive prevention of cardiovascular events

Filip Málek
Nemocnice Na Homolce, Ambulance srdečního selhání

A high proportion of patients with arterial hypertension have not only high blood pressure, but also impaired lipid metabolism.

Hypertension and dyslipidaemia are frequent; therefore, timely and simultaneous intervention on the two significant risk factors

for atherosclerosis and cardiovascular events is necessary. A fixed triple combination of two antihypertensive drugs with statin is

a modern approach in comprehensive prevention of cardiovascular events.

Keywords: hypertension, dyslipidaemia, primary prevention, fixed combination, perindopril, amlodipine, atorvastatin

Published: October 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Málek F. Lipertance - a novel agent in comprehensive prevention of cardiovascular events. Praktické lékárenství. 2016;12(5):170-172.
Download citation

References

  1. Conroy R, Pyörälä K, Fitzgerald AP, et al. SCORE project group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24: 987-1003. Go to original source... Go to PubMed...
  2. Patel A and ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcome in patients with type 2 diabetes mellitus (the ADVANCE trial). The Lancet 2007; 370: 829-840. Go to original source... Go to PubMed...
  3. Poulter NR, Peters R, Fletcher AE, et al. Role of blood pressure and other variables in the differential cardiovascular ebeny rates noted in Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet 2005; 366: 907-913. Go to original source... Go to PubMed...
  4. Sever PS, Dahlöf B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations in the Anglo-Scandinavian Cardiac Outcomes trial: Lipid Lowering Arm (ASCOT-LLA): a multicenter randomised controlled trial. Lancet 2003; 361: 1149-1158. Go to original source... Go to PubMed...
  5. Lipertance, SPC, dostupné na www: http://www.sukl.cz/modules/medication/detail.php?code=0205994&tab=texts.




Pharmacy for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.